Mobidiag signs several international agreements for the distribution of its diagnostic solutions Amplidiag ® and Novodiag ®

Tuesday, Feb 26, 2019

Mobidiag Ltd., a provider of marketable molecular diagnostics solutions that addresses the spread of antimicrobial resistance, today announced that it has several exclusive agreements with international partners for the distribution of its Amplidiag ® and Novodiag ® products in Europe and the Middle East.

Mobidiag has signed exclusive agreements for the distribution of Amplidiag ® and Novodiag ® with Helix2 for Greece and Interlab INTERAUTOMATIKA UAB for Latvia and Lithuania. Mobidiag also has its first contract in the Middle East with Ibn Rushd Medical & Scientific Equipment Co. for the distribution of Novodiag ® signed in Kuwait. The agreements come into force with immediate effect and initially for a period of two years.

Tuomas Tenkanen, CEO of Mobidiag, said: "We are very pleased to have expanded our sales presence to new international regions, including our first agreement in the Middle East. Mobidiag continues to see demand for the growth of Amplidiag ® and Novodiag ® solutions, and we are in discussion with multiple distributors in a number of international markets as consumers seek comprehensive diagnostics solutions for a variety of infectious diseases in both centralized and decentralized laboratories. "



Other News